Q-omics provides the consensus-scored RANP2 profile across patient tissues and cancer cell-line models. RANP2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, RANP2 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RANP2 RNA expression shows 12,798 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SARC, COAD, and GBM as cancer lineages where RANP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANP2 survival associations across molecular data types. RANP2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANP2 RNA expression–survival associations across cancer types. High RANP2 expression shows unfavorable associations in SARC, THYM, LUSC, THCA, PAAD and KIRC. The SARC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for RANP2 RNA expression.
This table summarizes RANP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RANP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANP2 shows higher tumor expression in COAD, BRCA and LUSC. The COAD box plot shows higher RANP2 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p = .035).
This table shows molecular features associated with RANP2 in patient tissues and cancer cell lines. In patient samples, RANP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
